Background {#Sec1}
==========

In 1927, Otto Warburg described what would be called the "Warburg effect," in which tumour cells exhibited characteristic changes in metabolism, particularly the use of glycolysis rather than oxidative phosphorylation, despite the presence of adequate amounts of oxygen \[[@CR1], [@CR2]\]. Warburg believed that this process was the actual cause of neoplastic transformation \[[@CR3]\].

Tumour development is now known to be driven by genetic damage. However, mutations in some metabolic enzymes, such as succinate dehydrogenase (SDH) and fumaratehydratase (FH), both parts of the tricarboxylic acid (TCA) cycle, can drive neoplastic transformation, and intermediate products of metabolism can also promote neoplastic progression \[[@CR4]\].

Proliferating cancer cells have a high energy requirement to maintain homeostatic cellular processes. The shift in energy production to aerobic glycolysis, while allowing for more rapid production of adenosine triphosphate (ATP), yields far less energy than oxidative phosphorylation: there are two net molecules of ATP per glucose molecule in glycolysis versus 36 molecules of ATP via oxidative phosphorylation \[[@CR5]\].

The reasons for the glycolytic energy dependence of proliferating tumour cells are still being debated. Initially, it was believed that the mitochondria in tumours were intrinsically defective. However, it was determined that tumour mitochondria are actually functional, retaining the capacity for oxidative phosphorylation and consuming oxygen at similar rates to normal tissues \[[@CR6]\], although it should be appreciated that a degree of variability in mitochondrial activities exists across different neoplasms. Alternatively, high rates of glycolysis might be co-selected with factors that promote the expression of hypoxia-related genes (such as those required for angiogenesis) as an oxygen-independent energy source. Finally, increased intermediate products of glycolysis can easily be shunted into the biosynthetic pathways required for serine and nucleotide synthesis \[[@CR7]\].

According to Folkman's original theory \[[@CR8]\], the onset of hypoxia in tumour triggers angiogenesis, which in turn is essential for supplying neoplastic cells with nutrients and oxygen and evacuating metabolic waste and carbon dioxide. The best understood hypoxia signaling mechanism is the stabilization and post-transcription activation of the hypoxia-inducible factor (HIF) proteins, which lead to the activation of many different pathways, including the vascular endothelial growth factor (VEGF) pathway. The VEGF pathway prompts and supports neoangiogenesis and glycolysis. Hypoxia-inducible pathway activation also has other effects, which include reducing the activity of mammalian target of rapamycin (mTOR), which in turn can reignite autophagy and promote survival under stress \[[@CR9]\].

HIF is a heterodimer of an alpha subunit that is unstable in normoxia and a constitutively present and stable beta subunit. The hypoxia activation of HIF causes the heterodimer to bind to DNA at specific locations, called hypoxic response elements (HREs), eliciting the transcriptional up-regulation of genes required to respond appropriately to hypoxia \[[@CR9]\].

In addition to triggering the VEGF pathway, the ubiquitously expressed HIF1 isoform promotes the transcription of glucose transporter 1 (GLUT1), which activates glucose transport inside the cell, lactate dehydrogenase-A (LDH-A), which is involved in the glycolytic pathway, erythropoietin (EPO), which enhances erythropoiesis, and nitric oxide synthase (NOS), which promotes angiogenesis and vasodilatation \[[@CR9]\].

HIF1 also prevents the entry of pyruvate into the TCA cycle by inducing the expression of pyruvate dehydrogenase kinase 1 (PDK1), thus altering the expressed isoform of cytochrome *c* and inhibiting mitochondrial biogenesis. This process causes reduced levels of oxygen consumption and a shift away from oxidative phosphorylation. Interestingly, HIF1 can also be activated under normoxic conditions by a variety of oncogenic pathways, such as phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and by mutations in von Hippel-Lindau tumour suppressor (VHL), SDH, and FH \[[@CR10]\].

In the classic angiogenic pathway, VEGF binds to VEGF receptor 2 (VEGFR2) on endothelial cells, increasing the expression of the Notch ligand Delta-like 4 (DLL4) on the same cells. DLL4 then binds to its receptor Notch on the adjacent endothelium. Further expression of VEGFR2 and VEGFR1, as well as a smaller amount of VEGFR3, then follows, leading to triggering/amplification of the downstream phospholipase C familyγ (PLCγ)--protein kinase C (PKC)--Raf kinase--MAP kinase-ERK kinase (MEK)--mitogen-activated protein kinase (MAPK) pathway, concomitantly prompting cell proliferation and cell survival throughout the phosphoinositide 3-kinase (PI3 K)/protein kinase B (AKT) pathway \[[@CR11]\].

The switch to glycolysis in neoplasia was, according to Warburg, irreversible \[[@CR3]\], yet a more complex picture has emerged over the last decade. There have been observed instances in which oxidative phosphorylation predominates during neoplastic transformation \[[@CR12]\]. This variation between OxPhos and glycolysisin cancer cells has been increasingly linked to specific disturbances in cell signaling pathways \[[@CR13]\].

Additionally, tumours of the same genetic lineage can develop different metabolic adaptations depending on the host tissue from which they arise, suggesting that the stromal environment might play a crucial role in shaping the metabolic profile \[[@CR14]\]. The different molecular mechanisms being postulated to explain this variability of the Warburg effect include the following: inhibition of pyruvate dehydrogenase (PDH) by PDK1, reduction of mitochondrial biogenesis and inhibition of oxidative phosphorylation, both are caused by P53 inactivation and mutations \[[@CR15]\].

Warburg raised two important issues: first, how tumour cells are supplied with glucose; and second, how they are supplied with oxygen \[[@CR1]\]. Folkman's work addressed the latter question with the hypothesis that tumour growth is strictly angiogenesis-dependent \[[@CR16]\]. The work undertaken to test this hypothesis led to the inclusion of "angiogenesis" as one of the hallmarks of cancer \[[@CR8]\].

Although there is strong evidence that angiogenesis frequently occurs in cancer, we also now know that this event does not always occur. Indeed, some tumours, called "non-angiogenic tumours," can grow without triggering new vessel formation by co-opting preexisting vessels \[[@CR17], [@CR18]\].

Non-angiogenic growth was first identified by histology in primary and metastatic lung carcinomas because neoplastic cells filled the alveolar spaces, co-opting the pre-existing capillary network and exhibiting a characteristic "chicken-wire" appearance \[[@CR17]\]. A gene expression signature for non-angiogenic non-small cell lung cancer (NSCLC) was published in 2005 \[[@CR19]\]. Surprisingly, rather than the classic angiogenesis-related genes, the differentially expressed genes were involved in mitochondrial metabolism, transcription, protein synthesis, and the cell cycle. Lack of differential mRNA expression between tumour phenotypes was noted for genes classically associated with hypoxia and angiogenesis. This result suggested that the response to hypoxia does not necessarily trigger neovascularisation, as would be observed in angiogenic tumours, but could actually be dependent on the genetic background of neoplastic cells, and in some instances, it could lead to metabolic reprogramming \[[@CR19]\]. We therefore postulated that the degree to which a tumour will rely on angiogenic or non-angiogenic growth could be associated with a variety of events, including hypoxia, pseudo-hypoxia, and metabolic re-programming.

In the first part of the present study, we investigated whether there were truly no differences in the expression of hypoxia-and angiogenesis-related proteins between angiogenic and non-angiogenic tumours, as suggested by mRNA profiling. We also investigated the degree of these proteins expression and the expression of some mitochondrial biogenesis proteins via immunohistochemistry. Notably high cytoplasmic P53 expression in non-angiogenic tumours, compared to angiogenic tumours, was found after completing the first part of this study. We therefore performed a second investigation, in which we examined and sequenced the *p53* gene in these tumours.

Methods {#Sec2}
=======

Tissue specimens {#Sec3}
----------------

Clinical specimens of NSCLCs were obtained from a series of consecutive patients who underwent surgical treatment at the John Radcliffe Hospital, Oxford, UK. This collection had ethical committee approval (study number C02.216---The pathophysiology of human neoplasia). The tissues were formalin-fixed and paraffin-embedded. Tissue microarrays were constructed using the Beecher Instrument MTA-1 manual arrayer (Beecher Instruments, Inc., Sun Prairie, WI, USA). Up to four suitable areas of appropriate tumour were chosen from a slide stained with hematoxylin and eosin (H&E), avoiding areas of necrosis.

Immunohistochemical staining of tissue sections {#Sec4}
-----------------------------------------------

The 4-μm sections were cut from paraffin blocks and mounted on glass histology slides. Non-specific protein binding was blocked by incubating with 2.5% normal horse serum (Vector Laboratories, Burlingame, CA, USA), and the primary antibody was then applied. Details of all of the antibodies used are presented in Table [1](#Tab1){ref-type="table"}. Substitution of the primary antibody with phosphate-buffered saline (PBS) served as a negative control. The slides were then counterstained with hematoxylin for 20 s.Table 1Antibodies used for immunohistochemistryAntigenCloneSourceHIF1ESEE122Abcam (Cambridge, UK)HIF2EP109bNDCLS (University of Oxford, John Radcliffe Hospital, Oxford, UK)CA9M75BioScience Slovakia s.r.o. (Bratislava, Slovakia)VEGFAVG-1NDCLSTYMPPGF44NDCLSKDRFLK1(A3)Santa Cruz Biotechnology, Inc. (Dallas, TX, USA)KDRp3434aNDCLSFIHFIH162c/D6NDCLSPHD1PHD112/GNDCLSPHD2366G/76NDCLSPHD3EG188cNDCLSDLL4D4/37NDCLSTSP18A6B-TSP-1Leica Microsystems (UK) Ltd. and Novocastra Reagents (Milton Keynes, UK)CXCR4MAB 172R&D System (Minneapolis, MN, USA)EPHB2AF496R&D SystemEPHB3R&D AF432R&D SystemEPHB4R&D AF446R&D SystemSOD130F11NovocastraBCL2124Dako (Cambridgeshire, UK)FOSPolyclonal 27436AbcamEGFEGF 10AbcamEGFRF4AbcamBNIP3Ana40Sigma-Aldrich Company Ltd. (Dorset, UK)P53DO7DakoPI3Ab 40755AbcamSP1SP1 polyclonalAbcamSTAT3E121-21AbcamLON20H1NDCLSMEF2DMEF2D polyclonalAbcamJMYHMY117ANDCLSTRAP1TR-1ALabVision (TorsbySjöväg, Värmdö, Sweden)GSTGST3/GST piAbcamNCAMIB6NovocastraCHGAFLEX polyclonalDakoSYP299Novocastra*HIF* hypoxia-inducible factor; *CA9* carbonic anhydrase 9; *VEGFA* vascular endothelial growth factor A; *TYMP* thymidine phosphorylase; *KDR* vascular endothelial growth factor receptor 2; *KDRp34* vascular endothelial growth factor p34; *FIH* factor-inhibiting HIF; *PHD* prolyl hydroxylase dehydrogenase; *DLL4* Delta-like 4; *TSP1* thymidine phosphorylase 1; *CXCR4* chemokine (C-X-C motif) receptor 4; *EPH* ephrin; *SOD1* superoxide dismutase 1; *BCL2* B cell lymphoma 2; *FOS* FBJ murine osteosarcoma viral oncogene homolog; *EGF* epidermal growth factor; *EGFR* epidermal growth factor receptor; *BNIP3* BCL2/adenovirus E1B 19 kDa interacting protein 3; *PI3* peptidase inhibitor 3; *SP1* Sp1 transcription factor; *STAT3* signal transducer and activator of transcription 3; *LON* Lon protease; *MEF2D* myocyte enhancer factor 2D; *JMY* junction-mediating and regulatory protein, p53 cofactor; *TRAP1* TNF receptor-associated protein 1; *GST* glutathione S-transferase; *NCAM* neural cell adhesion molecule; *CHGA* chromogranin A; *SYP* synaptophysin

Scoring {#Sec5}
-------

The immunohistochemical staining was scored for cytoplasmic and nuclear localization and, when present, for membrane staining. Two observers scored the slides. Intensity was scored on a scale of 0--3 (0 = no staining, 1 = weak, 2 = moderate, 3 = strong staining). The percentage of positive cells was recorded on a scale from 0 to 4 (1 = 1%--10%, 2 = 11%--50%, 3 = 51%--80%, 4 = 81%--100%) or alternatively on a continuous scale from 0% to 100%. The intensity and percentage values were then multiplied to provide a score called the "intensity percentage score" (IPS), the maximum score of which ranged from 12 to 300 \[[@CR20]\].

Disputed scores were discussed and a consensus reached. For tissue microarrays, cores that did not contain tumour tissue or that were more than 50% incomplete were excluded. The number of cases scored for each marker was between a minimum of 73 and a maximum of 194 cases for angiogenic tumours and between a minimum of 48 and a maximum of 73 cases for non-angiogenic tumours.

Statistical analysis {#Sec6}
--------------------

To evaluate the association between protein biomarker expression and angiogenic status, the Mann--Whitney two-tailed non-parametric test was performed using GraphPad Prism statistical analysis software, version 4 (GraphPad Software Inc., San Diego, CA, USA).

Pathway visualization {#Sec7}
---------------------

Three lists were made: two of proteins more highly expressed in angiogenic or non-angiogenic tumours at least in one subcellular location and the third of proteins always equally expressed in all of their subcellular localizations (Table [2](#Tab2){ref-type="table"}). To visualize the pathways associated with these proteins, each list was imported into the Web-based Enricher facility (<http://amp.pharm.mssm.edu/Enrichr/>) \[[@CR21]\]. The data were visualized from the online databases for gene ontologies (GO biological process and GO cellular component) and for pathways \[Kyoto Encyclopedia of Genes and Genomes (KEGG) 2015, WikiPathways 2015, Reactome 2015, and Panther\]. The results were visualized by bar graph sorted by combined score.Table 2Lists of proteins used for pathway visualization using the EnrichrWebd facility \[[@CR21]\]Expression statusProteinsEqual expression in both tumour typesHIF2, VEGFA, TYMP, KDR, KDRp34, FIH, PHD1, SOD1, EPHB4, BCL2, EGFR, FGF, SP1, LON, MEF2D, RPSA^a^, CHGA, SYPHigher expression in angiogenic tumours than in non-angiogenic tumours in at least one subcellular locationHIF1, PHD2, PHD3 (cytoplasmic), CXCRN, TSP, DLL4, BNIP3, PI3, EGF, FOS, STAT3, ITGB3^a^, ITGAV^a^Higher expression in non-angiogenic tumours than in angiogenic tumours in at least one subcellular locationCA9, PHD3 (nuclear), EPHB2, EPHB3, NCAM, P53, TRAP1, JMY, GST*FGF* fibroblast growth factor; *RPSA* ribosomal protein SA; *ITGB3* integrin, beta 3; *ITGAV* integrin alpha-V; *HIF* hypoxia-inducible factor; *CA9* carbonic anhydrase 9; *VEGFA* vascular endothelial growth factor A; *TYMP* thymidine phosphorylase; *KDR* vascular endothelial growth factor receptor 2; *KDRp34* vascular endothelial growth factor p34; *FIH* factor-inhibiting HIF; *PHD* prolyl hydroxylase dehydrogenase; *DLL4* Delta-like 4; *TSP1* thymidine phosphorylase 1; *CXCR4* chemokine (C-X-C motif) receptor 4; *EPH* ephrin; *SOD1* superoxide dismutase 1; *BCL2* B cell lymphoma 2; *FOS* FBJ murine osteosarcoma viral oncogene homolog; *EGF* epidermal growth factor; *EGFR* epidermal growth factor receptor; *BNIP3* BCL2/adenovirus E1B 19 kDa interacting protein 3; *PI3* peptidase inhibitor 3; *SP1* Sp1 transcription factor; *STAT3* signal transducer and activator of transcription 3; *LON* Lon protease; *MEF2D* myocyte enhancer factor 2D; *JMY* junction-mediating and regulatory protein, p53 cofactor; *TRAP1* TNF receptor-associated protein 1; *GST* glutathione S-transferase; *NCAM* neural cell adhesion molecule; *CHGA* chromogranin A; *SYP* synaptophysin^a^Data for RPSA are from Ref. \[[@CR18]\] and for ITGB3 and ITGAV are from Ref. \[[@CR23]\]

P53 sequencing {#Sec8}
--------------

Genomic DNA was isolated from 33 specimens of NSCLC (25 angiogenic cases, seven non-angiogenic cases, and one undetermined case) and five specimens of peri-tumour lung tissues. The coding regions corresponding to exons 3--9 (amino acids 25--331) were sequenced. DNA was whole-genome amplified using GenomiPhi (GE Healthcare, Piscataway, NJ, USA). The primers for polymerase chain reaction (PCR) amplification and subsequent sequencing reactions are described in Table [3](#Tab3){ref-type="table"}. PCR was performed using ThermoStart PCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA), following the manufacturer's protocol. PCR products were purified and bidirectionally sequenced using the BigDye Terminator cycle sequencing kit, version 1.1 (Applied Biosystems, Foster City, CA, USA), and an ABI 3100 Genetic Analyzer (Applied Biosystem, Paisley, UK). Sequence data were analyzed using Mutation Surveyor, version 3.25 (Softgenetics, State College, PA, USA). Predicted effects on protein were assessed in silico using PolyPhen2 software (<http://genetics.bwh.harvard.edu/pph2/>). Fisher's two-sided exact test was performed to compare mutation frequencies in angiogenic versus non-angiogenic cases. All sequencing experiments were performed in duplicate.Table 3Primers for polymerase chain reaction (PCR) amplification and subsequent P53 sequencing reactionsPrimerSequenceAnnealing temperature (°C)Amplicon length (bp)Exon 3--4Forward: GTGGGAAGCGAAAATTCCAT\
Reverse: GCCAGGCATTGAAGTCTCAT60506Exon 5--6Forward: TGTTCACTTGTGCCCTGACT\
Reverse: TTAACCCCTCCTCCCAGAGA60467Exon 7Forward: GAGCTTGCAGTGAGCTGAGA\
Reverse: GGGATGTGATGAGAGGTGGA\
EX7F_seq CCTGCTTGCCACAGGTCT (to be used for sequencing instead of Exon 7 forward primer)61.5390Exon 8--9Forward: GACAAGGGTGGTTGGGAGTA\
Reverse: GCCCCAATTGCAGGTAAAAC60500

Results {#Sec9}
=======

Immunohistochemical staining {#Sec10}
----------------------------

The complete results for the cytoplasmic and membranous expression are reported in Table [4](#Tab4){ref-type="table"}, and those for nuclear expression are reported in Table [5](#Tab5){ref-type="table"}, while a summary of these results appears in Table [6](#Tab6){ref-type="table"}. The complete original results of ontology and pathway visualization appear in Additional file [1](#MOESM1){ref-type="media"}.Table 4Cytoplasmic and membranous expression of the proteins in angiogenic versus non-angiogenic non-small cell lung cancers (NSCLCs)ProteinIntensity percentage score (IPS) of protein expression*P* valueTumour type with higher expressionAngiogenic tumoursNon-angiogenic tumoursHIF16.22 ± 0.336.00 ± 0.480.87--HIF20.00 ± 0.000.00 ± 0.00Not applicable--CA9 cytoplasm2.38 ± 0.163.50 ± 0.23\<0.001Non-angiogenicCA9 membrane4.00 ± 0.403.30 ± 0.880.62--VEGFA8.83 ± 0.357.38 ± 0.780.07--TYMP3.20 ± 0.542.21 ± 0.320.28--KDR94.56 ± 1.6497.80 ± 1.54\>0.05--KDRp3410.40 ± 0.3010.55 ± 0.620.71--FIH9.10 ± 0.3210.00 ± 0.470.22--PHD13.74 ± 0.274.20 ± 0.480.47--PHD23.50 ± 0.302.46 ± 0.530.02AngiogenicPHD32.70 ± 0.093.38 ± 0.17\<0.001Non-angiogenicDLL4vessels2.34 ± 0.101.53 ± 0.09\<0.001AngiogenicTSP stroma16.98 ± 2.752.00 ± 1.74\<0.001AngiogenicCXCR42.47 ± 0.202.34 ± 0.310.92EPHB27.78 ± 0.279.06 ± 0.33\<0.01Non-angiogenicEPBH3 cytoplasm159.3 ± 8.84202.20 ± 9.95\<0.01Non-angiogenicEPBH3 membrane23.83 ± 7.2386.51 ± 12.78\<0.001Non-angiogenicEPHB47.82 ± 0.267.40 ± 0.380.57--SOD14.36 ± 0.459.39 ± 4.220.27--BCL21.05 ± 0.250.68 ± 0.350.54--FOS8.05 ± 0.375.31 ± 0.55\<0.001AngiogenicEGFR203.40 ± 10.79166.30 ± 25.740.33--EGF18.90 ± 3.0314.44 ± 4.150.72--FGF9.20 ± 0.429.72 ± 0.710.74--BNIP36.08 ± 0.365.92 ± 0.820.88--P530.28 ± 0.122.28 ± 0.56\<0.001Non-angiogenicPI34.62 ± 0.364.92 ± 0.610.51--SP13.70 ± 0.373.38 ± 0.550.86--STAT38.78 ± 0.397.11 ± 0.790.03AngiogenicLON102.50 ± 11.20134.20 ± 17.100.18--MEF2D cytoplasm50.11 ± 4.1665.67 ± 9.660.25--MEF2Dmembrane60.00 ± 7.1267.50 ± 12.670.47--JMY1.84 ± 0.182.42 ± 0.310.05Non-angiogenicTRAP14.22 ± 0.285.48 ± 0.31\<0.01Non-angiogenicGST cytoplasm236.20 ± 7.16249.80 ± 11.400.23--GSTmembrane28.44 ± 5.5269.38 ± 14.03\<0.01Non-angiogenicNCAM0.40 ± 0.093.92 ± 0.07\<0.001Non-angiogenicCHGA0.08 ± 0.040.27 ± 0.14\>0.05--SYP0.12 ± 0.050.44 ± 0.15\>0.05--All data are presented as mean ± standard error*HIF* hypoxia-inducible factor; *CA9* carbonic anhydrase 9; *VEGFA* vascular endothelial growth factor A; *TYMP* thymidine phosphorylase; *KDR* vascular endothelial growth factor receptor 2; *KDRp34* vascular endothelial growth factor p34; *FIH* factor-inhibiting HIF; *PHD* prolyl hydroxylase dehydrogenase; *DLL4* Delta-like 4; *TSP1* thymidine phosphorylase 1; *CXCR4* chemokine (C-X-C motif) receptor 4; *EPH* ephrin; *SOD1* superoxide dismutase 1; *BCL2* B cell lymphoma 2; *FOS* FBJ murine osteosarcoma viral oncogene homolog; *EGF* epidermal growth factor; *EGFR* epidermal growth factor receptor; *BNIP3* BCL2/adenovirus E1B 19 kDa interacting protein 3; *PI3* peptidase inhibitor 3; *SP1* Sp1 transcription factor; *STAT3* signal transducer and activator of transcription 3; *LON* Lon protease; *MEF2D* myocyte enhancer factor 2D; *JMY* junction-mediating and regulatory protein, p53 cofactor; *TRAP1* TNF receptor-associated protein 1; *GST* glutathione S-transferase; *NCAM* neural cell adhesion molecule; *CHGA* chromogranin A; *SYP* synaptophysin*--* Indicates equal expressionTable 5Nuclear expression of the proteins in angiogenic versus non-angiogenic NSCLCsProteinIntensity percentage score (IPS) of protein expression*P* valueTumour type with higher expressionAngiogenic tumoursNon-angiogenic tumoursHIF15.49 ± 0.313.79 ± 0.390.01AngiogenicVEGFA6.09 ± 0.525.62 ± 0.320.74--TYMP1.94 ± 0.221.16 ± 0.210.42--KDR231.20 ± 8.55229.80 ± 9.88\>0.05--KDRp3411.69 ± 0.1611.45 ± 0.390.77--FIH7.50 ± 0.358.15 ± 0.720.50--PHD13.10 ± 0.342.50 ± 0.350.99--PHD22.56 ± 0.271.41 ± 0.350.02AngiogenicPHD32.18 ± 0.130.65 ± 0.20\<0.001AngiogenicCXCR45.13 ± 0.233.72 ± 0.37\<0.01AngiogenicEPHB23.26 ± 0.264.91 ± 0.35\<0.001Non-angiogenicEPBH399.27 ± 7.41147.30 ± 9.23\<0.001Non-angiogenicEPHB45.56 ± 0.305.73 ± 0.340.81--SOD14.21 ± 0.455.00 ± 0.910.44--C-FOS7.50 ± 0.525.53 ± 0.750.05AngiogenicEGF235.20 ± 5.60214.8 ± 8.680.01AngiogenicFGF7.51 ± 0.388.68 ± 0.760.11--BNIP33.96 ± 0.400.00 ± 0.00\<0.001AngiogenicP532.66 ± 0.362.32 ± 0.530.91--PI30.53 ± 0.130.00 ± 0.00\<0.02AngiogenicSP15.31 ± 0.464.04 ± 0.600.24--STAT37.80 ± 0.396.31 ± 0.810.09--MEF2D251 ± 4.62243.10 ± 8.040.38--JMY2.01 ± 0.172.60 ± 0.270.07--TRAP11.57 ± 0.184.58 ± 0.32\<0.001Non-angiogenicGST243.30 ± 6.15244.10 ± 10.910.55--CHGA0.00 ± 0.000.34 ± 0.12\>0.05--All data are presented as mean ± standard error*HIF* hypoxia-inducible factor; *CA9* carbonic anhydrase 9; *VEGFA* vascular endothelial growth factor A; *TYMP* thymidine phosphorylase; *KDR* vascular endothelial growth factor receptor 2; *KDRp34* vascular endothelial growth factor p34; *FIH* factor-inhibiting HIF; *PHD* prolyl hydroxylasedehydrogenase; *DLL4* Delta-like 4; *TSP1* thymidine phosphorylase 1; *CXCR4* chemokine (C-X-C motif) receptor 4; *EPH* ephrin; *SOD1* superoxide dismutase 1; *BCL2* B cell lymphoma 2; *FOS* FBJ murine osteosarcoma viral oncogene homolog; *EGF* epidermal growth factor; *EGFR* epidermal growth factor receptor; *BNIP3* BCL2/adenovirus E1B 19 kDa interacting protein 3; *PI3* peptidase inhibitor 3; *SP1* Sp1 transcription factor; *STAT3* signal transducer and activator of transcription 3; *LON* Lon protease; *MEF2D* myocyte enhancer factor 2D; *JMY* junction-mediating and regulatory protein, p53 cofactor; *TRAP1* TNF receptor-associated protein 1; *GST* glutathione S-transferase; *NCAM* neural cell adhesion molecule; *CHGA* chromogranin A; *SYP* synaptophysin*--* Indicates equal expressionTable 6Protein biomarker expression in angiogenic and non-angiogenic NSCLCs according to their intracellular localizationExpression statusIntracellular expression localizationProteinsEqual expression in both tumour typesNuclearVEGFA, TYMP, KDR, KDRp34, FIH, EPHB4, PHD1, SOD1, FGF, P53, SP1, STAT3, MEF2D, JMY, GST, CHGACytoplasmHIF1, HIF2, VEGFA, TYMP, KDR, KDRp34, FIH, PHD1, SOD1, CXCR4, EPHB4, BCL2, EGF, EGFR, FGF, BNIP3, PI3, SP1, LON, MEF2D, GST, CHGA, SYPMembraneCA9, MEF2DHigher expression in angiogenic tumours than in non-angiogenic tumours in at least one subcellular locationNuclearHIF1, PHD2, PHD3, CXCR4, BNIP3, PI3, EGF, FOSCytoplasmPHD2, TSP (stroma), DLL4 (endothelium), FOS, STAT3MembraneNoneHigher expression in non-angiogenic tumours than in angiogenic tumours in at least one subcellular locationNuclearEPHB2, EPHB3,TRAP1CytoplasmCA9, PHD3, EPHB2, EPHB3, NCAM, P53, TRAP1, JMYMembraneEPHB3, GST*HIF* hypoxia-inducible factor; *CA9* carbonic anhydrase 9; *VEGFA* vascular endothelial growth factor A; *TYMP* thymidine phosphorylase; *KDR* vascular endothelial growth factor receptor 2; *KDRp34* vascular endothelial growth factor p34; *FIH* factor-inhibiting HIF; *PHD* prolyl hydroxylase dehydrogenase; *DLL4* Delta-like 4; *TSP1* thymidine phosphorylase 1; *CXCR4* chemokine (C-X-C motif) receptor 4; *EPH* ephrin; *SOD1* superoxide dismutase 1; *BCL2* B cell lymphoma 2; *FOS* FBJ murine osteosarcoma viral oncogene homolog; *EGF* epidermal growth factor; *EGFR* epidermal growth factor receptor; *BNIP3* BCL2/adenovirus E1B 19 kDa interacting protein 3; *PI3* peptidase inhibitor 3; *SP1* Sp1 transcription factor; *STAT3* signal transducer and activator of transcription 3; *LON* Lon protease; *MEF2D* myocyte enhancer factor 2D; *JMY* junction-mediating and regulatory protein, p53 cofactor; *TRAP1* TNF receptor-associated protein 1; *GST* glutathione S-transferase; *NCAM* neural cell adhesion molecule; *CHGA* chromogranin A; *SYP* synaptophysin

In Table [7](#Tab7){ref-type="table"}, a selection of pathways shows that proteins expressed in both types of tumours are associated with angiogenesis-, VEGF-, and oxidative stress-related pathways. The non-angiogenic tumours are distinguished from the angiogenic tumours by having higher levels of proteins related to ephrin pathways, response to hypoxia, HIF1 regulation by oxygen, and transcription of HIF-controlled genes but lower levels of proteins involved in stromal cell--cell signaling and adhesion, integrins, and Delta-Notch- and EGF-related signaling.Table 7Selection of visualized pathwaysProteins equally expressed in angiogenic and non-angiogenictumoursProteins up-regulated in angiogenic tumoursProteins up-regulated in non-angiogenic tumoursPathwayDatabasesPathwayDatabasesPathwayDatabasesFocal adhesionKEGG, WikiPathwaysFocal adhesionKEGG, WikiPathways----VEGF-relatedKEGG, Panther, Reactome--------AngiogenesisPanther, WikiPathwaysAngiogenesisPantherAngiogenesisPanther----Itegrin signallingPanther----Oxidative stressPanther, WikiPathways--------Cell response to stressReactome------------Delta-NotchWikiPathways--------Collagen-related pathwaysReactome--------Cell--cell communicationReactome--------Integrin signalingPanther----EGF-related pathwaysWikiPathways, Panther------------Response to HypoxiaReactomeEphrins signalingReactome----Ephrins-related pathwaysReactome--------Regulation of HIF by oxygenReactome--------Regulation of genes by HIFReactome--------Nitrogen metabolismKEGG

Gene ontology analysis confirmed that proteins usually associated with angiogensis were present in both types of tumours, whereas higher levels of proteins associated with Notch, extracellular matrix, and cell adhesion were present in the truly angiogenesis-producing tumours. However, in the tumours that grow in a non-angiogenic fashion, proteins associated with mitochondria, cell biogenesis, carbonic dehydratase, ephrins, and axon guidance-related functions were more commonly detected (Table [8](#Tab8){ref-type="table"}).Table 8Selection of visualized ontologiesProteins equally expressed in angiogenic and non-angiogenic tumoursProteins up-regulated in angiogenic tumoursProteins up-regulated in non-angiogenic tumoursOntologyGO-ontology databaseOntologyGO-ontology databaseOntologyGO-ontology databaseCell migration/sprouting angiogenesis\
GO.0002042Biological processImmune response-activating signals\
GO.0002757Biological processRegulation of synapses\
GO.0051965Biological processEndothelial cell migration\
GO.0043534Biological processImmune response-regulating cell signaling\
GO.0002768Biological processAxon guidance and neuronal regulation\
GO.0031290\
GO.0007413\
GO.0021952\
GO.0021955\
GO.0008038Biological processVEGF signaling pathways\
GO.0038084Biological processMesodermal cell differentiation\
GO.0048333Biological process--------Activation of immune response\
GO.0002253Biological process------------Positive regulation cell biogenesis\
GO.0044089Biological process----Basement membrane\
GO.0005604Cell component--------Extracellular matrix part\
GO.0044420Cell componentMitochondrial intermembrane space and matrix\
GO.0005758\
GO.0005759Cell component----Complex involve in cell adhesion\
GO.0098636Cell component----PDGF receptor-binding\
GO.0005161Molecular functionFibronectin- and extracellular matrix-binding\
GO.0001968\
GO.0050840Molecular functionEphrin receptor activity\
GO.0005003Molecular functionExtracellular matrix-binding\
GO.0050840Molecular functionNotch-binding\
GO.0005112Molecular functionCarbonate dehydratase activity\
GO.0004089Molecular function--------Axon guidance\
GO.0008046Molecular function

Sequencing {#Sec11}
----------

The higher level of *p53* expression in the cytoplasm of the non-angiogenic tumours, as compared with the angiogenic tumours, was one of the most striking results (Table [9](#Tab9){ref-type="table"}) and raised the question of whether non-angiogenic cells had wild-type *p53* or a different set of mutations from the angiogenic tumours. Our results showed that *p53*mutations were observed in eight of 25 angiogenic cases (32.0%) but in five of seven non-angiogenic cases (71.4%) (*P* = 0.091 by Fisher's two-tailed exact test) (Table [9](#Tab9){ref-type="table"}).Table 9Summary of *p53* mutations detected in non-angiogenic and angiogenic NSCLC casesSample IDSample typeMutation locationMutation typeDomainPredicted effect on protein activity104Non-angiogenicc.761T\>TA; p.I254SMissenseHCD IVDamaging105Non-angiogenicc.734G\>GA; p.G245DMissenseHCD IVDamaging121Non-angiogenicc.488A\>AG; p.Y163CMissenseDNA bindingDamaging152Non-angiogenicc.634T\>TG; p.F212 VMissenseDNA bindingBenign249Non-angiogenicc.314G\>GA; p.G105DMissenseDNA bindingDamaging133Angiogenicc.511G\>GT; p.E171XNonsense (truncated protein)HCD IIITruncating138Angiogenicc.824G\>GA; p.C275YMissenseHCD IVDamaging139Angiogenicc.het_del216C; p.V73 Wfs48XFrameshift (truncated protein)ProlinerichTruncating141Angiogenicc.407A\>AC; p.Q136PMissenseHCD IIDamaging98Angiogenicc.524G\>GA; p.R175HMissenseHCD IIIPotentially damaging147Angiogenicc.524G\>GA; p.R175HMissense274Angiogenicc.471_472TC\>GA; p.V157GMissenseDNA bindingDamagingAffected domains are listed. The software used to predict the functional effect of the detected sequence changes was PolyPhen_2 (<http://genetics.bwh.harvard.edu/ggi/pph2/c2ea64efde6f039a5ca76a2a264ae4f3cf922360/1121012.html> [)]{.ul}*HCD* highly conserved domain

All of the detected mutations were heterozygous, and almost all of them corresponded to hot spots previously reported in different tumour types (<http://genetics.bwh.harvard.edu/ggi/pph2/c2ea64efde6f039a5ca76a2a264ae4f3cf922360/1121012.html>). The locations of the mutations were randomly distributed across the sequenced region. No specific pattern of mutation location seemed to be related to tumour subtype, angiogenic or non-angiogenic (Fig. [1](#Fig1){ref-type="fig"} and Table [9](#Tab9){ref-type="table"}).Fig. 1Localization of the mutations detected on the *p53* gene. The sequenced region is indicated with an *orange* line in the figure above. Mutation locations are indicated with *arrowheads* (*purple* mutations found in angiogenic samples; *gray*: mutations found in non-angiogenic samples). Human P53 protein (HP53) can be divided into five domains, each corresponding to specific functions: *yellow* is the highly conserved domain I (HCD I)/transactivation domain; *red* is the second transactivation domain, which is proline-rich; *blue* is the DNA-binding domain essential for *p53*-DNA interactions that also contains HCD II-V and is the target of 90% of the *p53* mutations found in human cancers; *green* is the nuclear export signal (NES) localized in the oligomerization domain of *p53*

Discussion {#Sec12}
==========

As initially suggested by our mRNA profiling work \[[@CR19]\] and also confirmed by the immunohistochemical data presented here, we failed to reveal significant differences between angiogenic and non-angiogenic NSCLCs as far as the expression of proteins associated with the classic hypoxia/angiogenesis pathway is concerned. Because neovascularisation is found in some tumours but not in others, we suggest that activation of the classical angiogenic pathways is necessary, but not sufficient, to induce the sprouting of new vessels in cancer.

The higher levels of expression of proteins associated with extracellular matrix, cell adhesion, and inflammation were in agreement with the observed presence of tumour-associated stroma and chronic inflammation in many angiogenic tumours \[[@CR18], [@CR22]\]. mRNA profiling of these tumours has equally shown that stromal remodeling, cell adhesion, and inflammation are enhanced in angiogenesis \[[@CR19]\]. Both mRNA and immunohistochemical data suggest a crucial role in angiogenic cancers for FBJ murine osteosarcoma viral oncogene homolog (FOS), a protein involved in cell proliferation, remodeling, and inflammation. The question remains of whether tissue remodeling is a consequence or a cause of the triggering of angiogenesis. Because non-angiogenic tumours usually preserve the pre-existing architecture, we hypothesize that the triggering of tissue destruction could be a secondary step necessary for the activation of angiogenesis. Nonetheless, this process would be far from a general rule because we have observed, in a subset of NSCLC, that angiogenesis can occur in the absence of tissue destruction \[[@CR23]\]. Clearly, other mechanisms must exist.

If classical angiogenesis pathways are similarly active in both angiogenic and non-angiogenic tumours, how does their biology differ? Our previous transcriptional profiling work demonstrated higher levels of mRNA coding for molecules associated with oxidative phosphorylation and mitochondrial biogenesis in non-angiogenic tumours \[[@CR19]\]. In the present study, we did not examine components of the oxidative phosphorylation pathway, although we did investigate the expression of some proteins involved in mitochondrial functions. Our results showed that proteins related to mitochondria and to cell biogenesis-promoting processes were more highly expressed in non-angiogenic tumours than in angiogenic tumours. This feature was consistent with higher mitochondrial regulatory activity and a possible metabolic switch in non-angiogenic tumours. Again, whether this switch is a cause or an effect of HIF activation remains unclear.

Interestingly, our data suggested increased involvement of response to hypoxia and to HIF regulation by oxygen in non-angiogenic tumours. We hence speculate that, in these tumours, although the HIF pathway failed to induce new vessel formation, it could well be involved in metabolic reprogramming.

Finally, we noted markedly higher levels of cytoplasmic P53 expression in non-angiogenic tumours than in angiogenic tumours via immunohistochemistry. In a pilot study, we sequenced *p53* in a limited number of angiogenic and non-angiogenic NSCLCs. Non-angiogenic tumours had a higher incidence of mutations, which were all missense mutations, whereas angiogenic tumours had an amalgam of frame shifts and missense and nonsense mutations. Because *p53* also affects mitochondrial respiration \[[@CR24]\], it will be necessary to investigate further how the observed *p53* mutations could functionally affect its ability to regulate respiration and/or angiogenesis.

Conclusions {#Sec13}
===========

On the basis of our observations collected so far, from the mRNA profiling, immunohistochemical and histopathologic data, we conclude that all tumours, angiogenic and non-angiogenic, experience hypoxia/HIF and VEGF pathway activation. However, angiogenesis does not always ensue. Based on these findings, we suggest that in non-angiogenic tumours, HIF pathway activation could be the driving force toward metabolic reprogramming.

Additional file {#Sec15}
===============

10.1186/s40880-016-0082-6 Visualization of ontologies and pathways likely to be associated with the patterns of protein expression as detected by immunohistochemistry on angiogenic versus non-angiogenic non-small cell lung carcinomas (NSCLCs). The results represent the combined score, which is computed by the Enrich application by taking the log of the *P* value from the Fisher's exact test and multiplying it by the *z* score of the deviation from the expected rank. The length of the bar represents the significance of that specific geneset or term. In addition, the brighter the color is, the more significant that term is. The following are the original results classified according to the databases used (KEGG 2015, Panther, Reactome 2015, WikiPathways 2015, GO-Biological Process, GO-Cell Component, and GO-Molecular Function).
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